J.Jpn. Surg. Soc.. 80(3): 274-283, 1979
Original article
POSSIBILITY OF IMMUNOLOGICAL DIAGNOSIS AND THERAPY FOR THE BRAIN TUMORS
－CELLULAR IMMUNITY AND SPECIFIC IMMUNOTHERAPY OF AUTOCHTHONOUS LYMPHOCYTE INNOCULATION－
|
Department of Neurosurgery, Juntendo University, School of Medicine Mung-Sang Lee |
In this study, we discussed the cellular immunity, especially a method of lymphocyte blastogenesis, and the clinical trials of specific immunotherapy of autochthonous lymphocyte innoculation into the postoperative dead space of the tumor through the Ommaya reservoier.
The assay of blastogenesis herein used is based on measurement of the rate of incorporation of 3H-uridine into RNA. This assay has been applicable to phytohemagglutinin-P (PHA) and the antigens extracted from tumor. The results were as follows;
In normal control groups, stimulation index (SI) was 7.85±3.76. But SI of brain tumors was 5.32±2.34,which was significantly lower than those of control groups. Furthermore, in malignant groups (glioma and metastatic brain tumor), SI was 4.96±2.14, more lower than that of benign groups (6.05±2.75). However, generally SI was a high value in the favorable convalescent cases of malignant tumors, while on the contrary, SI was lower in unfavorable cases of benign tumors.
In SI against antigens extracted from tumor, there has not been observed any capable difference between autochthonous lymphocyte and control.
We have so far conducted the specific immunotherapy against 14 cases of brain tumors, among which 7 cases are still survived.
We had the belief that the therapy was effective for malignant brain tumors, judging from
1) autopsy findings, 2) reoperative macro and microscopic findings, 3) PPD reaction and 4) peripheral lymphocyte counts.
To read the PDF file you will need Adobe Reader installed on your computer.